The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use
ABSTRACT: Thirty-five peptides selected from functionally-relevant SARS-CoV-2 spike (S), membrane (M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) DNA-genotyped Aotus monkeys and matched with HLA-DRb1* molecules for use in humans. This was aimed at producing...
- Autores:
-
Rugeles López, María Teresa
Aguilar Jiménez, Wbeimar
Flórez Álvarez, Lizdany
Pabón, Laura
Patarroyo, Manuel Elkin
Patarroyo, Manuel Alonso
Alba, Martha P.
Bermúdez, Abriana
Rout, Ashok k.
Griesinger, Cristina
Suarez Martínez, Carlos Fernando
Aza Conde, Jorge
Reyes, Cesar
Avendaño, Catalina
Samacá, Jhoan
Camargo, Anny
Silva, Yolanda
Forero, Martha
González, Edgardo
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2021
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/36775
- Acceso en línea:
- https://hdl.handle.net/10495/36775
- Palabra clave:
- SARS-CoV-2
Péptidos
Peptides
Anticuerpos ampliamente neutralizantes
Broadly Neutralizing Antibodies
Anticuerpos Virales
Antibodies, Viral
Vacunas contra la COVID-19
COVID-19 Vaccines
Cadenas HLA-DRB1
HLA-DRB1 Chains
Glicoproteína de la Espiga del Coronavirus
Spike Glycoprotein, Coronavirus
Virosis
Virus Diseases
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by/2.5/co/
| id |
UDEA2_2762d1a3ef3564754dea6ac42b9c5c5b |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/36775 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use |
| title |
The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use |
| spellingShingle |
The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use SARS-CoV-2 Péptidos Peptides Anticuerpos ampliamente neutralizantes Broadly Neutralizing Antibodies Anticuerpos Virales Antibodies, Viral Vacunas contra la COVID-19 COVID-19 Vaccines Cadenas HLA-DRB1 HLA-DRB1 Chains Glicoproteína de la Espiga del Coronavirus Spike Glycoprotein, Coronavirus Virosis Virus Diseases |
| title_short |
The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use |
| title_full |
The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use |
| title_fullStr |
The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use |
| title_full_unstemmed |
The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use |
| title_sort |
The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human use |
| dc.creator.fl_str_mv |
Rugeles López, María Teresa Aguilar Jiménez, Wbeimar Flórez Álvarez, Lizdany Pabón, Laura Patarroyo, Manuel Elkin Patarroyo, Manuel Alonso Alba, Martha P. Bermúdez, Abriana Rout, Ashok k. Griesinger, Cristina Suarez Martínez, Carlos Fernando Aza Conde, Jorge Reyes, Cesar Avendaño, Catalina Samacá, Jhoan Camargo, Anny Silva, Yolanda Forero, Martha González, Edgardo |
| dc.contributor.author.none.fl_str_mv |
Rugeles López, María Teresa Aguilar Jiménez, Wbeimar Flórez Álvarez, Lizdany Pabón, Laura Patarroyo, Manuel Elkin Patarroyo, Manuel Alonso Alba, Martha P. Bermúdez, Abriana Rout, Ashok k. Griesinger, Cristina Suarez Martínez, Carlos Fernando Aza Conde, Jorge Reyes, Cesar Avendaño, Catalina Samacá, Jhoan Camargo, Anny Silva, Yolanda Forero, Martha González, Edgardo |
| dc.contributor.researchgroup.spa.fl_str_mv |
Inmunovirología |
| dc.subject.decs.none.fl_str_mv |
SARS-CoV-2 Péptidos Peptides Anticuerpos ampliamente neutralizantes Broadly Neutralizing Antibodies Anticuerpos Virales Antibodies, Viral Vacunas contra la COVID-19 COVID-19 Vaccines Cadenas HLA-DRB1 HLA-DRB1 Chains Glicoproteína de la Espiga del Coronavirus Spike Glycoprotein, Coronavirus Virosis Virus Diseases |
| topic |
SARS-CoV-2 Péptidos Peptides Anticuerpos ampliamente neutralizantes Broadly Neutralizing Antibodies Anticuerpos Virales Antibodies, Viral Vacunas contra la COVID-19 COVID-19 Vaccines Cadenas HLA-DRB1 HLA-DRB1 Chains Glicoproteína de la Espiga del Coronavirus Spike Glycoprotein, Coronavirus Virosis Virus Diseases |
| description |
ABSTRACT: Thirty-five peptides selected from functionally-relevant SARS-CoV-2 spike (S), membrane (M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) DNA-genotyped Aotus monkeys and matched with HLA-DRb1* molecules for use in humans. This was aimed at producing the first minimal subunit-based, chemically synthesised, immunogenic molecules (COLSARSPROT) covering several HLA alleles. They were predicted to cover 48.25% of the world’s population for 6 weeks (short-term) and 33.65% for 15 weeks (long-lasting) as they induced very high immunofluorescent antibody (IFA) and ELISA titres against S, M and E parental native peptides, SARS-CoV-2 neutralising antibodies and host cell infection. The same immunological methods that led to identifying new peptides for inclusion in the COLSARSPROT mixture were used for antigenicity studies. Peptides were analysed with serum samples from patients suffering mild or severe SARS-CoV-2 infection, thereby increasing chemically-synthesised peptides’ potential coverage for the world populations up to 62.9%. These peptides’ 3D structural analysis (by 1 H-NMR acquired at 600 to 900 MHz) suggested structural functional immunological association. This first multi-protein, multi-epitope, minimal subunit-based, chemically-synthesised, highly immunogenic peptide mixture highlights such chemical synthesis methodology’s potential for rapidly obtaining very pure, highly reproducible, stable, cheap, easily-modifiable peptides for inducing immune protection against COVID-19, covering a substantial percentage of the human population. |
| publishDate |
2021 |
| dc.date.issued.none.fl_str_mv |
2021 |
| dc.date.accessioned.none.fl_str_mv |
2023-10-03T15:48:19Z |
| dc.date.available.none.fl_str_mv |
2023-10-03T15:48:19Z |
| dc.type.spa.fl_str_mv |
Artículo de investigación |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
| dc.type.coarversion.spa.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| status_str |
publishedVersion |
| dc.identifier.citation.spa.fl_str_mv |
Patarroyo ME, Patarroyo MA, Alba MP, Pabon L, Rugeles MT, Aguilar-Jimenez W, Florez L, Bermudez A, Rout AK, Griesinger C, Suarez CF, Aza-Conde J, Reyes C, Avendaño C, Samaca´ J, Camargo A, Silva Y, Forero M and Gonzalez E (2021) The First Chemically Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. Front. Immunol. 12:724060. |
| dc.identifier.issn.none.fl_str_mv |
1664-3224 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/36775 |
| dc.identifier.doi.none.fl_str_mv |
10.3389/fimmu.2021.724060 |
| identifier_str_mv |
Patarroyo ME, Patarroyo MA, Alba MP, Pabon L, Rugeles MT, Aguilar-Jimenez W, Florez L, Bermudez A, Rout AK, Griesinger C, Suarez CF, Aza-Conde J, Reyes C, Avendaño C, Samaca´ J, Camargo A, Silva Y, Forero M and Gonzalez E (2021) The First Chemically Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. Front. Immunol. 12:724060. 1664-3224 10.3389/fimmu.2021.724060 |
| url |
https://hdl.handle.net/10495/36775 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Front. Immunol. |
| dc.relation.citationendpage.spa.fl_str_mv |
16 |
| dc.relation.citationissue.spa.fl_str_mv |
724060 |
| dc.relation.citationstartpage.spa.fl_str_mv |
1 |
| dc.relation.citationvolume.spa.fl_str_mv |
12 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Frontiers in Immunology |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ https://creativecommons.org/licenses/by/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
16 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Frontiers in immunology |
| dc.publisher.place.spa.fl_str_mv |
Lausana, Suiza |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/466adcfe-938f-4087-b1c3-86f680f1d1cc/download https://bibliotecadigital.udea.edu.co/bitstreams/8553a277-6f15-462d-a5e9-c5090d89ae76/download https://bibliotecadigital.udea.edu.co/bitstreams/462ab99e-a573-4a2b-9f95-aae20c477906/download https://bibliotecadigital.udea.edu.co/bitstreams/187cae46-ef42-4b0d-89ea-ceff628127ef/download https://bibliotecadigital.udea.edu.co/bitstreams/0f4eac2d-ba78-4958-99bc-bfc7542f992e/download |
| bitstream.checksum.fl_str_mv |
d7792b4b6a8aeccb891d0ca32a8cd8e1 54b25d00d9da26324cf2a57ee111c3e9 8a4605be74aa9ea9d79846c1fba20a33 95e20f67aec103c7fb0db042c6aa5954 50ea29bfba4556f66a5b744dd522455c |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052563806289920 |
| spelling |
Rugeles López, María TeresaAguilar Jiménez, WbeimarFlórez Álvarez, LizdanyPabón, LauraPatarroyo, Manuel ElkinPatarroyo, Manuel AlonsoAlba, Martha P.Bermúdez, AbrianaRout, Ashok k.Griesinger, CristinaSuarez Martínez, Carlos FernandoAza Conde, JorgeReyes, CesarAvendaño, CatalinaSamacá, JhoanCamargo, AnnySilva, YolandaForero, MarthaGonzález, EdgardoInmunovirología2023-10-03T15:48:19Z2023-10-03T15:48:19Z2021Patarroyo ME, Patarroyo MA, Alba MP, Pabon L, Rugeles MT, Aguilar-Jimenez W, Florez L, Bermudez A, Rout AK, Griesinger C, Suarez CF, Aza-Conde J, Reyes C, Avendaño C, Samaca´ J, Camargo A, Silva Y, Forero M and Gonzalez E (2021) The First Chemically Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. Front. Immunol. 12:724060.1664-3224https://hdl.handle.net/10495/3677510.3389/fimmu.2021.724060ABSTRACT: Thirty-five peptides selected from functionally-relevant SARS-CoV-2 spike (S), membrane (M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) DNA-genotyped Aotus monkeys and matched with HLA-DRb1* molecules for use in humans. This was aimed at producing the first minimal subunit-based, chemically synthesised, immunogenic molecules (COLSARSPROT) covering several HLA alleles. They were predicted to cover 48.25% of the world’s population for 6 weeks (short-term) and 33.65% for 15 weeks (long-lasting) as they induced very high immunofluorescent antibody (IFA) and ELISA titres against S, M and E parental native peptides, SARS-CoV-2 neutralising antibodies and host cell infection. The same immunological methods that led to identifying new peptides for inclusion in the COLSARSPROT mixture were used for antigenicity studies. Peptides were analysed with serum samples from patients suffering mild or severe SARS-CoV-2 infection, thereby increasing chemically-synthesised peptides’ potential coverage for the world populations up to 62.9%. These peptides’ 3D structural analysis (by 1 H-NMR acquired at 600 to 900 MHz) suggested structural functional immunological association. This first multi-protein, multi-epitope, minimal subunit-based, chemically-synthesised, highly immunogenic peptide mixture highlights such chemical synthesis methodology’s potential for rapidly obtaining very pure, highly reproducible, stable, cheap, easily-modifiable peptides for inducing immune protection against COVID-19, covering a substantial percentage of the human population.COL001244416 páginasapplication/pdfengFrontiers in immunologyLausana, Suizahttp://creativecommons.org/licenses/by/2.5/co/https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2The first chemically-synthesised, highly immunogenic anti-SARS-CoV 2 peptides in DNA genotyped aotus monkeys for human useArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionSARS-CoV-2PéptidosPeptidesAnticuerpos ampliamente neutralizantesBroadly Neutralizing AntibodiesAnticuerpos ViralesAntibodies, ViralVacunas contra la COVID-19COVID-19 VaccinesCadenas HLA-DRB1HLA-DRB1 ChainsGlicoproteína de la Espiga del CoronavirusSpike Glycoprotein, CoronavirusVirosisVirus DiseasesFront. Immunol.16724060112Frontiers in ImmunologyPublicationORIGINALRugelesMaria_2021_TheFirstChemicallySynthesised.pdfRugelesMaria_2021_TheFirstChemicallySynthesised.pdfArtículo de Investigaciónapplication/pdf3431057https://bibliotecadigital.udea.edu.co/bitstreams/466adcfe-938f-4087-b1c3-86f680f1d1cc/downloadd7792b4b6a8aeccb891d0ca32a8cd8e1MD51trueAnonymousREADRugelesMaria_2021_First_Chemically_Synthesised.epubRugelesMaria_2021_First_Chemically_Synthesised.epubArtículo de Investigaciónapplication/epub+zip507917https://bibliotecadigital.udea.edu.co/bitstreams/8553a277-6f15-462d-a5e9-c5090d89ae76/download54b25d00d9da26324cf2a57ee111c3e9MD53falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/462ab99e-a573-4a2b-9f95-aae20c477906/download8a4605be74aa9ea9d79846c1fba20a33MD52falseAnonymousREADTEXTRugelesMaria_2021_TheFirstChemicallySynthesised.pdf.txtRugelesMaria_2021_TheFirstChemicallySynthesised.pdf.txtExtracted texttext/plain100427https://bibliotecadigital.udea.edu.co/bitstreams/187cae46-ef42-4b0d-89ea-ceff628127ef/download95e20f67aec103c7fb0db042c6aa5954MD54falseAnonymousREADTHUMBNAILRugelesMaria_2021_TheFirstChemicallySynthesised.pdf.jpgRugelesMaria_2021_TheFirstChemicallySynthesised.pdf.jpgGenerated Thumbnailimage/jpeg14830https://bibliotecadigital.udea.edu.co/bitstreams/0f4eac2d-ba78-4958-99bc-bfc7542f992e/download50ea29bfba4556f66a5b744dd522455cMD55falseAnonymousREAD10495/36775oai:bibliotecadigital.udea.edu.co:10495/367752025-03-27 00:22:41.587http://creativecommons.org/licenses/by/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo= |
